CEACAM-5

CEACAM-5 詳細

英語名Carcinoembryonic antigen related cell adhesion molecule 5市販薬剤の数0
治験薬の数18ターゲットの別称CEA Cell Adhesion Molecule 5,CEACAM5,Meconium antigen 100,CEA,Carcinoembryonic Antigen Related Cell Adhesion Molecule 5,Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5,Carcinoembryonic Antigen,CD66e Antigen,CD66e
研究&開発段階Phase 3 Clinical
英語名Carcinoembryonic antigen related cell adhesion molecule 5
ターゲットの別称CEA Cell Adhesion Molecule 5,CEACAM5,Meconium antigen 100,CEA,Carcinoembryonic Antigen Related Cell Adhesion Molecule 5,Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5,Carcinoembryonic Antigen,CD66e Antigen,CD66e
市販薬剤の数0
治験薬の数18
研究&開発段階Phase 3 Clinical

CEACAM-5 製品リスト

  • 属性

    Protein (18)Cell (2)Cell Grade Beads (1)Beads (1)

  • 製品ライブラリ

    オンライン (22)

  • Human (16)Mouse (2)Cynomolgus (3)Rhesus macaque (1)

  • タグ

    His Tag (8)His Tag & Avi Tag (4)Fc Tag (3)Fc Tag & Avi Tag (1)Llama IgG Fc Tag (2)- (4)

  • マーカー

    Unconjugated (11)Biotin-labeled (5)FITC Labeled (2)- (4)

CEACAM-5バックグランド

Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) is also Carcinoembryonic antigen (CEA), Meconium antigen 100, CD antigen CD66e, CEACAM5 belongs to the immunoglobulin superfamily and CEA family. CEACAM5 contains seven Ig-like (immunoglobulin-like) domains. CEACAM5 is homodimer protein which binding of E.coli Dr adhesins leads to dissociation of the homodimer. CEACAM5 is cell surface glycoprotein that plays a role in cell adhesion and in intracellular signaling. CEACAM5 is receptor for E.coli Dr adhesins.

CEACAM-5分子の別称

CEACAM-5,CD66e,CEA,Meconium antigen 100

治験薬に関する情報

英語名研究コード研究開発ステージ会社適応症臨床試験
Tusamitamab RavtansineSAR-408701; IBI-126Phase 3 ClinicalImmunogen IncAdenocarcinoma; Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Lung Neoplasms; Metastatic breast cancer; Neoplasms; Pancreatic Neoplasms; Stomach Neoplasms
詳細
SGM-101SGM-101Phase 3 ClinicalSurgimab SasBrain Diseases; Brain metastases; Brain Neoplasms; Colonic Diseases; Colonic Neoplasms; Colorectal Neoplasms; Gastrointestinal Diseases; Gastrointestinal Neoplasms; Intestinal Diseases; Intestinal Neoplasms; Pancreatic Neoplasms; Rectal Neoplasms
詳細
Cancer vaccine (BN ImmunoTherapeutics/National Cancer Institute)CVAC-301; CV-301Phase 2 ClinicalTherion BiologicsAdenocarcinoma; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Colorectal Neoplasms; Cystadenocarcinoma; Intestinal Neoplasms; Melanoma; Neoplasm Metastasis; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Solid tumours; Urinary Bladder Neoplasms
詳細
NEO-201NEO-201Phase 2 ClinicalNational Cancer Institute, Precision Biologics IncCarcinoma, Non-Small-Cell Lung; Squamous Cell Carcinoma of Head and Neck; Uterine Cervical Neoplasms; Uterine Neoplasms
詳細
Anti-CEA CAR T cell therapy (Shanghai GeneChem)Phase 2 ClinicalShanghai Genechem Co LtdColorectal Neoplasms; Liver Neoplasms
詳細
BMS-986490BMS-986490Phase 2 ClinicalBristol-Myers Squibb CompanySolid tumours
詳細
LM-24C5LM-24C5Phase 2 ClinicalLaNova Medicines LtdNeoplasms; Solid tumours
詳細
Precemtabart tocentecanM-9140; M9140Phase 2 ClinicalMerck KGaA, Darmstadt, GermanyCarcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms
詳細
MFE-23-CD3z T cell therapy (Cancer Research Technology)Phase 1 ClinicalCancer Research TechnologyNeoplasms
詳細
anti-CEA CAR T-cell therapy (Shanghai First Song Therapeutics)Phase 1 ClinicalShanghai Simcere Pharmaceutical Co LtdColorectal Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms; Small Intestine Cancers; Solid tumours; Stomach Neoplasms
詳細
125-Iodine-labeled MFE-23Phase 1 ClinicalCancer Research UKNeoplasms
詳細
anti-CEA CAR-T cell therapy (Sorrento/TNK therapeutics/Roger Williams Medical Center)Phase 1 ClinicalBeth Israel Deaconess Medical CenterAdenocarcinoma; Liver Neoplasms; Neoplasm Metastasis; Neoplasms; Pancreatic Neoplasms; Solid tumours
詳細
CEACAM5-TOPO1 ADC (Bristol-Myers Squibb Company)Phase 1 ClinicalBristol-Myers Squibb CompanySolid tumours
詳細
124I-M5APhase 1 ClinicalCity Of Hope National Medical Center, National Cancer InstituteColorectal Neoplasms
詳細
IBI-3020IBI3020; IBI-3020Phase 1 ClinicalXinda Biomedical Technology (Hangzhou) Co LtdNeoplasm Metastasis; Solid tumours
詳細
SGN-CEACAM5CPF-08046050; SGN-CEACAM5C; SAR445953; SAR-445953Phase 1 ClinicalSanofi, Seagen IncCarcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Gastroesophageal Junction Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Stomach Neoplasms
詳細
EBC-129EBC129; EBC-129Phase 1 ClinicalExperimental Drug Development CentreSolid tumours
詳細
GB-5012GB-5012ClinicalShanghai Genbase Biotechnology Co LtdColonic Neoplasms
詳細

レビュー

  • n***l2026-08-21
    0評価
    This protein was purchased for target testing. The product was very easy to reconstitute and produced accurate results. The shipping speed of the product was more efficient than estimated which was greatly appreciated. We enjoy ordering high quality products from Acro.
  • 詳細
  • 製品リスト
  • レビュー
  • 治験薬に関する情報
お問い合わせ

お問い合わせ
グローバル:+1 800-810-0816(Toll Free)

メールアドレス
order.jp@acrobiosystems.com

アクロバイオシステムズ株式会社
〒101-0051
東京都千代田区神田神保町1-32-8